Foghorn Therapeutics Advances Pipeline with Key Oncology and Immunology Milestones
Event summary
- FHD-909 Phase 1 trial advancing as planned, targeting SMARCA4-mutant NSCLC.
- Selective EP300 degrader program shows promise in multiple myeloma; IND targeted for 2027.
- Novel oral small molecule in immunology and inflammation on track for IND in 2027.
- $168 million cash runway extends into first half of 2028.
The big picture
Foghorn Therapeutics is leveraging its Gene Traffic Control® Platform to expand beyond oncology into immunology and inflammation, reflecting a broader industry trend of diversifying therapeutic pipelines. The company's strategic collaboration with Lilly underscores the potential of its selective SMARCA2 inhibitor program, while its strong cash position provides a buffer for continued innovation.
What we're watching
- Clinical Progress
- Whether FHD-909 can demonstrate efficacy in combination studies with pembrolizumab.
- Pipeline Expansion
- The pace at which Foghorn advances its immunology and inflammation program toward IND.
- Financial Sustainability
- How long the current cash runway can support ongoing R&D and operational expenses.
Related topics